PFIZER has voluntarily withdrawn
Mylotarg (gemtuzumab
ozogamicin) from the US market at
the request of the Food and Drug
Administration.
The medication is used for the
treatment of acute myeloid
leukaemia (AML) and the pullout
follows results of a recent clinical
trial which raised “new concerns
about the product’s safety”.
The drug, which was approved in
May 2000 under the FDA’s
accelerated approval scheme, also
failed to demonstrate clinical
benefit to patients according to
several years of postmarketing
experience.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jun 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jun 10
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.